ClinicalTrials.gg
Active, not recruitingNCT05415072Updated Jul 28, 2026

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

A Phase 1/2 interventional study of DYP688 in Metastatic Uveal Melanoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 11 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Enrollment
44th of 163
66 · median 36
Started
2022
with 12 others
Phase 1/2
21 of 191
8 open now
Primary completion
2027-10
later than 28 of 50 live
Registered
159th of 191
by date

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 44th largest by enrollment of the 163 interventional ones that give a count, is one of 13 that started in 2022, is one of 21 in phase 1/2, reaches primary completion later than 28 of the 50 other live ones, and was the 159th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

Read the detailed description

This is a First in Human (FIH), phase I/II, open label, multi-center study of DYP688 as a single agent. There will be two parts to this study: a phase I, dose escalation part followed by a phase II part. Dose escalation will be conducted in patients with MUM and other melanomas harboring GNAQ/11 mutations. Once the MTD and/or RD(s) is determined in the dose escalation part, the study may continue with a phase II part. The phase II part will be conducted in two groups of patients with MUM, a prior tebentafusp-treated group and a tebentafusp-naïve group. In addition to MUM, a third group of patients with non-uveal GNAQ/11 mutant melanomas may also be explored. This cohort may be opened based on emerging data from the dose escalation part of the study.

03

Conditions studied

  • Metastatic Uveal Melanoma

Keywords

  • Phase I/II
  • DYP688
  • melanoma
  • GNAQ/11 mutations
  • cancer
  • malignant melanoma
  • eye cancer
  • ocular melanoma
  • uveal melanoma
  • cutaneous melanoma
  • mucosal melanoma
  • neoplasms, eye
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients in the dose escalation part must be ≥ 18 years of age at the time of (ICF) signature. In the phase II part, patients ≥ 12 years of age at the time of informed consent may be eligible for enrollment (not applicable in countries where enrollment is restricted by the local health authority to patients ≥ 18 years of age). Patients must have a minimum weight of 40 kg.
  • performance status ≤ 1 for patients ≥ 18 years of age; performance status ≥ 70 for patients ≥ 16 and \< 18 years of age; Lansky performance status ≥ 70 for patients ≥ 12 and \< 16 years of age
  • Patients must be suitable and willing to undergo study required according to the treating institution's own guidelines and requirements. If a biopsy is not medically feasible, exceptions may be considered after documented discussion with Novartis.

For all patients in Dose Escalation

  • MUM: uveal melanoma with or cytologically confirmed disease. Patient must be either treatment naive or have received any number of prior lines and progressed on most recent therapy
  • Non-MUM: advanced cutaneous or mucosal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 mutation based on local data

For patients in Phase II

  • Tebentafusp naïve group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following standard therapies or that has no satisfactory alternative therapies
  • Tebentafusp pre-treated group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease. Patients must be previously treated with tebentafusp and have progressed
  • Non-MUM: patients with diagnosis of cutaneous or mucosal melanomas harboring GNAQ/11 mutations based on local data, with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies

Exclusion criteria

Exclusion Criteria:

  • Malignant disease, other than that being treated in this study.
  • Active , i.e. symptomatic brain metastases or known .
  • Evidence of active bleeding or bleeding diathesis or significant coagulopathy (including familial) or a medical condition requiring long term systemic anticoagulation that would interfere with .
  • History of anaphylactic or other severe / infusion reactions to ADCs or monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
  • Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:

    • 2 weeks for fluoropyrimidine therapy
    • 4 weeks for radiation therapy or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment.
    • 4 weeks or ≤ 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other agent.
    • 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosoureas and mitomycin C.
    • 4 weeks for immuno-oncologic therapy, such as , PD-1, or PD-L1 antagonists.
  • and / or uncontrolled heart disease such as congestive heart failure requiring treatment ( grade ≥ 2) or clinically significant arrhythmia despite medical treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Phase I: Dose Escalation

    Patients with metastatic uveal melanoma or other GNAQ/11 mutant melanomas

    Drug: DYP688

  • Experimental
    Phase II: Tebe naive group

    Patients with metastatic uveal melanoma that has not received prior treatment with tebentafusp

    Drug: DYP688

  • Experimental
    Phase II: Tebe pre-treated

    Patients with metastatic uveal melanoma that have been previously treated with tebentafusp

    Drug: DYP688

  • Experimental
    Phase II: Non-uveal melanoma

    Optional Arm: To explore patients with non-uveal melanoma that harbor GNAQ or 11 mutations, based on emerging data from dose escalation

    Drug: DYP688

Interventions

  • DrugDYP688

    Single agent DYP688

06

What researchers measure

Primary outcomes

  1. Phase I (Dose Escalation): Incidence and severity of dose limiting toxicities (DLTs) during the first 28 days of treatment.

    A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with DYP688. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: 28 days

  2. Phase I (Dose Escalation): Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Assessment of safety of DYP688 as a single agent

    Time frame: 9 months

  3. Phase I (Dose Escalation): Frequency of dose interruptions, reductions, and discontinuations

    Assessment of tolerability of DYP688 as a single agent

    Time frame: 9 months

  4. Phase II: Overall Response rate (ORR) per RECIST 1.1

    ORR in Phase II will be evaluated by central review per RECIST 1.1.

    Time frame: 17 months

Secondary outcomes

  1. Phase I and Phase II: PK profile of DYP688 - Area under the concentration-time curve (AUC)

    Pharmacokinetic (PK) parameters will be determined by non-compartmental methods using pharmacokinetic profile of DYP688.

    Time frame: 26 months

  2. Phase I and Phase II: PK profile of DYP688 - Peak concentration (Cmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of DYP688.

    Time frame: 26 months

  3. Phase I and Phase II: PK profile of DYP688 - Total body clearance (CL)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of DYP688.

    Time frame: 26 months

  4. Phase I and Phase II: PK profile of DYP688 - Elimination half-life

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of DYP688.

    Time frame: 26 months

  5. Phase I and Phase II: Prevalence and incidence of anti-DYP688 antibodies

    Assess of immunogenicity (IG) of DYP688 as a single agent

    Time frame: 26 months

  6. Phase I (Dose Escalation): Best Overall Response (BOR) per RECIST v1.1

    Evaluation of preliminary anti-tumor activity of DYP688 as a single agent

    Time frame: 9 months

  7. Phase I (Dose Escalation): Overall Response Rate (ORR) per RECIST v1.1

    Evaluation of preliminary anti-tumor activity of DYP688 as a single agent

    Time frame: 17 months

  8. Phase II: Duration of response (DoR) per RECIST v1.1

    Evaluation of anti-tumor activity of DYP688 as a single agent

    Time frame: 17 months

  9. Phase II: Progression free survival (PFS) per RECIST v1.1

    Evaluation of anti-tumor activity of DYP688 as a single agent

    Time frame: 17 months

  10. Phase II: Disease Control Rate (DCR) per RECIST v1.1

    Evaluation of anti-tumor activity of DYP688 as a single agent

    Time frame: 17 months

  11. Phase II: Overall Survival (OS)

    Evaluation of the effect of DYP688 as a single agent on overall survival

    Time frame: 17 months

  12. Phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Assessment of safety of DYP688 as a single agent

    Time frame: 17 months

  13. Phase II: Frequency of dose interruptions, reductions, and discontinuations

    Assessment of tolerability of DYP688 as a single agent

    Time frame: 17 months

07

Study locations

11 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloane Ketterin Cancer Ctr
    New York, New York 10065, United States
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Paris, 75231, France
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Leiden, South Holland 2333 ZA, Netherlands
  • Novartis Investigative Site
    Madrid, 28050, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
08

References and documents

Publications

  • Carlino MS, Kapiteijn E, Piperno-Neumann S, Sullivan RJ, Carvajal R, Dummer R, Gromke T, Hassel JC, Kee D, Ramelyte E, Shoushtari AN, Wei AZ, Enk A, Handel EE, Montazeri K, Ramon-Patino J, Richly H, Rodrigues M, Sandhu S, Smithy J, Speetjens FM, Milanez-Almeida P, Chaudhury A, Hoffmaster K, Ising M, Otero JA, RamKumar T, Reynolds A, Sharaby S, Werner L, Yerramilli-Rao P, Calvo E. An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial. Nat Med. 2026 Jul 13. doi: 10.1038/s41591-026-04518-z. Online ahead of print. PubMed 42443515 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Oct 2027, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 10, 2022
StartActual
Jul 4, 2022
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05415072
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Jul 4, 2022
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion